Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Budget impact model discussion

6 evidence topics · 17 sources

Summary

Task force good-practice guidance lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker and presentation as a series of scenario analyses. For cretostimogene grenadenorepvec, two of these inputs are not yet available: a price, and a labeled population and dosing schedule. CG Oncology expects to complete its BLA “before the end of March 2027” and, after FDA feedback, plans to include high-grade papillary-only disease alongside CIS with or without papillary tumors.

The eligible population depends on which BCG-unresponsive disease is included. CG Oncology estimates up to 25,000 addressable patients with BCG-unresponsive NMIBC from internal research. In the nadofaragene firadenovec budget impact model of one million members, 5.5 adults with CIS ± Ta/T1 disease were eligible in Year 1, against 33.2 when papillary-only disease was added; that model applied 56.5% BCG treatment and 30% BCG unresponsiveness. The 2020 ICER review assumed 38% BCG non-response and derived 70,135 prevalent eligible individuals, of whom 18,956 (27%) had CIS. The authors of that model state that up to 80% of patients decline or are ineligible for cystectomy.

On costs, the Form 10-K describes cretostimogene as a six-week induction course, with three weekly maintenance doses every three months for the first 12 months and every six months for the next 24 months. Comparator list prices are $62,740.70 per Adstiladrin box (“4 vials x 20 ml”; instilled once every three months; October 2026), $35,800.00 per 400 mcg Anktiva vial (January 2025), and $25,034.88 per pembrolizumab dose given every 6 weeks (September 2026); no wholesale acquisition cost was found for the gemcitabine intravesical system, whose fourth-quarter 2026 Medicare Part B payment limit is $73,054.053 per 225 mg system. Each intravesical instillation also carries administration and surveillance costs (CPT 51720, 52000, 88112), and in the nadofaragene firadenovec model increased drug and administration costs were partially offset by savings from reduced progression, fewer cystectomies, and lower adverse event rates. In the published models, results were most influenced by uptake rate, drug cost, and target population size in the budget impact model, and the 5-year Markov model was sensitive to cost alone in one-way sensitivity analysis. The budget impact model and the cost-per-responder model were funded by Ferring Pharmaceuticals and Johnson & Johnson, and the nogapendekin alfa inbakicept analysis is a preliminary report from ImmunityBio.